Glenmark Pharmaceuticals ltd — Capital/Financing Update 2018

Sep 28, 2018

==> picture [33 x 33] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

September 28, 2018

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001

To,

The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Re: Intimation of proposed cash buyback in respect of Glenmark Pharmaceuticals Limited (“Company”) of its U.S.$200 million 2 per cent resettable onward starting equity linked securities due 28 June 2022 (“FCC Bonds”)

The Company had issued the FCC Bonds in 2016 which are currently listed on the Singapore Exchange Securities Trading Limited. Pursuant to our intimation letters dated 25 September 2018 and 28 September 2018, and the powers delegated to the Operations Committee by the Board of Directors of the Company, the Operations Committee in their meeting held today, approved that the Company is looking to buyback part of its FCC Bonds at repurchase price of 105% of the principal amount outstanding per FCC Bond up to an aggregate purchase price of U.S.$ 100 million plus accrued but unpaid interest. MUFG Securities Asia Limited and J. P. Morgan Securities Limited are appointed as dealer managers, on behalf of the Company to purchase such FCC Bonds. The Operations Committee meeting commenced at 09.45 a.m. and concluded at 10.10 a.m., and the Company has executed a dealer manager agreement in this respect.

We request you to take this on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH VINAYAK Digitally signed by HARISH VINAYAK KUBER KUBER Date: 2018.09.28 10:18:21 +05'30' Harish Kuber Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)

Note:

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE.

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com